- Inflammasome Therapeutics Completes Enrollment in Study for First Oral Dual Inflammasome Inhibitor for Ophthalmic and Neuroinflammatory Diseases September 2024
- Inflammasome Therapeutics Announces First Patient Dosed in Phase 1 Geographic Atrophy (GA) Clinical Trial April 2024
- Inflammasome Therapeutics Announces 1st Patient Dosed in Phase 1 DME Study of the Dual Inflammasome Inhibitor K8 January 2024
- Inflammasome Therapeutics to Enter Clinic with Treatment for Dry AMD November 2023
- New study shows multiple inflammasomes combine to cause lupus, macular degeneration and other neuroinflammatory diseases such as Alzheimer’s disease and multiple sclerosis December 2021
- Inflammasome Therapeutics’ CEO to Be Featured Speaker at Upcoming Virtual Summit on Inflammasomes November 2021
- Inflammasome Therapeutics’ Kamuvudines Continue to Show Promise for Future Treatment – and Potentially a Cure – for Blindness in Seniors September 2021
Inflammasome Therapeutics to Develop Dual Sustained-Release HIV Prevention and Birth Control Implant August 2021- Kamuvudines May be Answer to Preventing Blindness in Aging Population April 2021
- Inflammasome Therapeutics Says Study Published Today in Proceedings of the National Academy of Sciences Provides Human Data Confirming Potential of Company’s Proprietary Compounds for Prevention of Dry AMD February - 2021
- Inflammasome Therapeutics Says Study Approximately 130,000 People Reported in Nature Communications Points to Potential for Treatment or Prevention of Diabetes and Other Inflammasome-Mediated Diseases with Company's Drugs September - 2020
- Inflammasome Therapeutics Receives Grant to Develop Sustained Release Bioerodible Birth Control Implant from The Gates Foundation September - 2020
- Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases September - 2019d